Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN), a biotech company specializing in the treatment of inner ear diseases, announced it will present new data in two oral sessions at the American Neurotology Society’s (ANS) annual meeting, part of the Combined Otolaryngology Spring Meetings (COSM) at the Gaylord National Resort & Convention Center in National Harbor, Maryland from April 20-22, 2018.

The COSM conference brings together otolaryngolists of different specialties, head and neck surgeons, residents in training, medical students, and allied health professionals for the purpose of disseminating and exchanging advancements and clinical research at the forefront of the field of otolaryngology. The data being presented by Sensorion include results from a study of SENS-401 in preclinical models, designed to determine how long after hearing loss onset SENS-401 could be administered, and results from a study conducted in collaboration with the University of Connecticut (UConn Health) of a circulating blood biomarker for hearing loss.

The respective oral presentation titles and times are as follows:

Sensorion/UConn Health Joint Study Title:
Noise-Induced Trauma Produces a Temporal Pattern of Change in Serum Levels of the Outer Hair Cell Biomarker Prestin

Date & Time: Sunday, April 22, 8:55 AM EST
Location: Convention Center, Maryland C

Sensorion Study Title:
The Clinical Stage Otoprotectant SENS-401 Effectively Reduces Hearing Loss in Rats When Administered up to 96 hours after Severe Acoustic Trauma

Date & Time: Sunday, April 22, 10:50 AM EST
Location: Convention Center, Maryland C

“We are pleased to have the opportunity to present our independent data at COSM this year given SENS-401’s entry into Phase 2 trials in 2018, as well as our joint study data conducted in collaboration with UConn Health,” said Nawal Ouzren, CEO, Sensorion. “COSM is a premier platform for researchers working on the cutting edge of otolaryngology to showcase their data and we look forward to presenting results from both of these studies at this conference.”

About SENS-401

SENS-401, R-azasetron besylate, is a drug candidate that aims to protect and preserve inner ear tissue when lesions are present that can cause progressive or sequelar hearing impediments. A small molecule that can be taken orally or via an injection, SENS-401 has received Orphan Drug Designation in Europe for the treatment of sudden sensorineural hearing loss, and Orphan Drug Designation from the US FDA for the prevention of platinum-induced ototoxicity in a pediatric population.

Source: Sensorion